Your browser doesn't support javascript.
loading
Intravascular Administration of Acridine Orange and Zoledronate in a Bone Metastasis Model of Breast Cancer.
Shoji, Ryo; Tsuchie, Hiroyuki; Nagasawa, Hiroyuki; Hongo, Michio; Kasukawa, Yuji; Nozaka, Koji; Kudo, Daisuke; Saito, Hikaru; Abe, Kazunobu; Igarashi, Shun; Harata, Shuntaro; Kasama, Fumihito; Miyakoshi, Naohisa.
Afiliação
  • Shoji R; Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, Akita, Japan yebyayayeby@gmail.com.
  • Tsuchie H; Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
  • Nagasawa H; Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
  • Hongo M; Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
  • Kasukawa Y; Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
  • Nozaka K; Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
  • Kudo D; Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
  • Saito H; Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
  • Abe K; Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
  • Igarashi S; Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
  • Harata S; Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
  • Kasama F; Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
  • Miyakoshi N; Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
Anticancer Res ; 42(11): 5357-5363, 2022 Nov.
Article em En | MEDLINE | ID: mdl-36288846
ABSTRACT
BACKGROUND/

AIM:

This study evaluated the effect of haematogenous administration of acridine orange (AO) alone and in combination with zoledronate (ZOL) on bone metastases. MATERIALS AND

METHODS:

E0771 cells (1.0×105 cells/10 µl) were injected directly into the right femur of female mice. The mice were divided into five groups according to treatment (drugs and irradiation) and were reared and sacrificed after 6 weeks. Micro-computed tomography (µCT) was performed to calculate the destruction rate of the femur bone. We measured tumour weight and volume at sacrifice and performed terminal deoxynucleotidyl transferase dUTP Nick-End Labelling staining of tumours.

RESULTS:

At 4 weeks, the bone destruction rate was lower in the AO+ZOL group than in the radiation group. At 6 weeks, the AO+ZOL group had a lower bone destruction rate than the control and radiation groups; the ZOL group had a lower rate than the radiation group. The AO and AO+ZOL groups had suppressed tumour weight and volume compared to the control and radiation groups. The number of extraosseous apoptotic cells was higher in the AO+ZOL group than in all other groups except the AO group.

CONCLUSION:

In a model of local bone metastasis of breast cancer, haematogenous administration of AO reduced tumour size and more so when combined with ZOL.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Osteólise / Neoplasias Ósseas / Neoplasias da Mama / Conservadores da Densidade Óssea Limite: Animals Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Osteólise / Neoplasias Ósseas / Neoplasias da Mama / Conservadores da Densidade Óssea Limite: Animals Idioma: En Ano de publicação: 2022 Tipo de documento: Article